Jia Wang

4PUBLICATIONS
6CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jun 06, 2025
An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy.

|Feb 23, 2022
Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.

Juan Mu, Haobin Deng, Cuicui Lyu

|Nov 18, 2020
Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant.

Qing Li, Juan Mu, Jijun Yuan

|Apr 02, 2020
Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.

Jia Wang, Nan Mou, Zhenxing Yang

Pageof 1

Frequent Collaborators

3 joint publications

Qing Li

3 joint publications

Qi Deng

3 joint publications

Juan Mu

1 joint publications

Xin Li